Skip to main content

Illumina Leads $8M Financing Round in GenoLogics

Premium

Laboratory information management system software company GenoLogics said last week that it has closed an $8 million funding round led by Illumina, a new investor in the company.

The financing will be used to develop products for clinical applications and new desktop sequencing systems, and also to expand sales and marketing functions. As part of the deal, Illumina's senior vice president and chief commercial officer, Tristan Orpin, will join GenoLogics' board of directors.

The GenoLogics investment "will benefit our mutual sequencing customers," Orpin said in a statement.

The investment builds on a previous agreement the companies struck up earlier this year to co-sell GenoLogics' LIMS (IS 2/8/2011). In September, GenoLogics released a preconfigured package for Illumina sequencing.

According to GenoLogics CEO Michael Ball, the investment will help customers "overcome some of the most challenging barriers to next-generation sequencing adoption, namely data management."

Additional details of the financing round were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.